Edition:
United States

Veracyte Inc (VCYT.OQ)

VCYT.OQ on NASDAQ Stock Exchange Global Market

12.54USD
2:12pm EST
Change (% chg)

$-0.07 (-0.56%)
Prev Close
$12.61
Open
$12.50
Day's High
$12.72
Day's Low
$12.32
Volume
24,685
Avg. Vol
130,421
52-wk High
$15.50
52-wk Low
$5.25

Latest Key Developments (Source: Significant Developments)

Veracyte Inc Q4 Net Loss Per Common Share $0.24
Tuesday, 27 Feb 2018 04:00pm EST 

Feb 27 (Reuters) - Veracyte Inc ::VERACYTE ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS, PROVIDES 2018 FINANCIAL OUTLOOK.SEES FY 2018 REVENUE $81 MILLION TO $83 MILLION.QTRLY ‍REVENUE WAS $19.6 MILLION, AN INCREASE OF 7%​.‍EXPECTS FULL-YEAR 2018 CASH BURN IN RANGE OF $18 MILLION TO $22 MILLION​.QTRLY NET LOSS PER COMMON SHARE, BASIC AND DILUTED $0.24.FY2018 REVENUE VIEW $84.9 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Veracyte Announces Strategic Realignment And New Appointments To Advance Commercial Growth
Monday, 8 Jan 2018 07:30am EST 

Jan 8 (Reuters) - Veracyte Inc ::VERACYTE ANNOUNCES STRATEGIC REALIGNMENT AND NEW APPOINTMENTS TO ADVANCE COMMERCIAL GROWTH.- COMPANY REITERATES 2017 REVENUE AND CASH BURN GUIDANCE.- IS CONSOLIDATING CLINICAL, MEDICAL AND RESEARCH AND DEVELOPMENT FUNCTIONS INTO ONE DEPARTMENT.FY2017 EARNINGS PER SHARE VIEW $-0.87, REVENUE VIEW $71.3 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Veracyte posts Q3 loss per share $0.21
Monday, 6 Nov 2017 04:05pm EST 

Nov 6 (Reuters) - Veracyte Inc :Veracyte announces third quarter 2017 financial results.Q3 loss per share $0.21.Q3 revenue $17.5 million versus I/B/E/S view $19.5 million.Q3 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $71 million to $72 million.Veracyte Inc - ‍narrowing range of its annual cash burn guidance to $25 to $26 million​.  Full Article

Veracyte reports Q2 loss per share $0.22
Monday, 31 Jul 2017 04:05pm EDT 

July 31 (Reuters) - Veracyte Inc -:Veracyte announces second quarter 2017 financial results.Q2 revenue $18.4 million versus I/B/E/S view $18.3 million.Sees FY 2017 revenue $76 million to $84 million.Qtrly loss per share $0.22.Veracyte Inc says reiterates its 2017 annual revenue guidance of $76 to $84 million and annual cash burn of $25 to $27 million.Q2 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.FY2017 revenue view $77.0 million -- Thomson Reuters I/B/E/S.  Full Article

Veracyte says Anthem coverage for the Afirma gene expression classifier for use in thyroid cancer diagnosis
Thursday, 18 May 2017 12:18pm EDT 

May 18 (Reuters) - Veracyte Inc :Veracyte announces Anthem coverage for the Afirma® gene expression classifier for use in thyroid cancer diagnosis.Anthem Inc has issued positive coverage policy veracyte's Afirma Gene Expression Classifier (GEC) for use in thyroid cancer diagnosis.  Full Article

Veracyte announces Q1 revenue $16.4 million
Wednesday, 3 May 2017 04:05pm EDT 

May 3 (Reuters) - Veracyte Inc :Veracyte announces first quarter 2017 financial results.Q1 revenue $16.4 million versus I/B/E/S view $17.7 million.Sees FY 2017 revenue $76 million to $84 million.Veracyte Inc - Veracyte reiterates its 2017 annual revenue guidance of $76 to $84 million and annual cash burn of $25 to $27 million.Qtrly loss per share $0.24.Q1 revenue view $17.7 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.FY2017 revenue view $79.9 million -- Thomson Reuters I/B/E/S.  Full Article

Veracyte reports qtrly loss per share $0.14
Wednesday, 1 Mar 2017 04:05pm EST 

Veracyte Inc : Veracyte announces fourth quarter and full-year 2016 financial results, provides 2017 financial outlook . Veracyte Inc sees 2017 cash burn of $25 to $27 million, a reduction of 16 to 22 pct over prior year . Sees FY 2017 revenue $76 million to $84 million . Q4 revenue $18.3 million versus I/B/E/S view $17.5 million . Veracyte Inc - qtrly loss per share $0.14 . Q4 earnings per share view $-0.26, revenue view $17.5 million -- Thomson Reuters I/B/E/S .FY2017 earnings per share view $-0.93, revenue view $80.3 million -- Thomson Reuters I/B/E/S.  Full Article

Veracyte to expand patient access to the Afirma gene expression classifier in thyroid cancer diagnosis
Wednesday, 8 Feb 2017 08:00am EST 

Veracyte Inc : Veracyte to expand patient access to the Afirma gene expression classifier in thyroid cancer diagnosis through agreement with quest diagnostics . Says quest diagnostics is expected to begin offering test to its customers nationally in Q2 of 2017 . Says financial and other terms of agreement were not disclosed. .Physician clients of quest diagnostics will be able to order test on behalf of patients, refer patient specimens to co for genomic testing.  Full Article